Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells $67,218.40 in Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 18,416 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $3.65, for a total transaction of $67,218.40. Following the completion of the transaction, the chief executive officer now owns 3,400,778 shares of the company’s stock, valued at $12,412,839.70. This trade represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Organogenesis Price Performance

NASDAQ ORGO traded down $0.18 on Monday, hitting $3.50. The stock had a trading volume of 448,089 shares, compared to its average volume of 847,970. The firm has a 50-day moving average of $3.37 and a 200-day moving average of $2.97. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis Holdings Inc. has a 52-week low of $2.16 and a 52-week high of $4.70. The company has a market capitalization of $464.03 million, a price-to-earnings ratio of -58.33 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.11. The business had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period in the previous year, the business earned $0.02 earnings per share. Equities analysts expect that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Institutional Investors Weigh In On Organogenesis

Large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its holdings in shares of Organogenesis by 309.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock valued at $11,136,000 after buying an additional 3,005,450 shares in the last quarter. AQR Capital Management LLC grew its position in Organogenesis by 76.9% during the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after acquiring an additional 986,132 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Organogenesis by 19.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after acquiring an additional 333,123 shares in the last quarter. Wealth Dimensions Group Ltd. raised its stake in shares of Organogenesis by 435.9% during the second quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock worth $1,142,000 after acquiring an additional 331,840 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Organogenesis by 1,350.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock worth $265,000 after acquiring an additional 88,175 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.